Key Takeaways AstraZeneca shares declined Tuesday after reports that senior executives in China were potentially implicated ...

(Alliance News) - AstraZeneca PLC on Tuesday took the rare step of addressing a sharp fall in the company's share price. Shares in the Cambridge-based pharmaceuticals company slumped 8.2% to 10,138.10 ...

Analyst Etzer Darout of BMO Capital maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of $89.00.

AstraZeneca's (NASDAQ:AZN) selloff on Tuesday in response to reports that the company is facing a fraud investigation in ...

AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially ...

Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics ...

AstraZeneca shares fell 8% in London Tuesday, the biggest drop in four years following a fresh report that a Chinese investigation of the company has widened. AstraZeneca said last week that its China ...

The FTSE 100 index fell slightly on Tuesday as a potential China probe negatively impacted AstraZeneca. Concurrently, U.S.

AstraZeneca shares recorded their biggest one-day drop since March 2020 on Tuesday following a report that dozens of senior ...

Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...

AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...